Virtu Financial LLC bought a new stake in shares of Becton Dickinson and Co (NYSE:BDX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 1,439 shares of the medical instruments supplier’s stock, valued at approximately $364,000.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vestor Capital LLC raised its stake in Becton Dickinson and by 2.9% during the third quarter. Vestor Capital LLC now owns 62,156 shares of the medical instruments supplier’s stock valued at $15,723,000 after purchasing an additional 1,761 shares in the last quarter. Endurant Capital Management LP purchased a new stake in Becton Dickinson and in the 3rd quarter worth approximately $5,581,000. Redpoint Investment Management Pty Ltd boosted its stake in shares of Becton Dickinson and by 2.5% during the 3rd quarter. Redpoint Investment Management Pty Ltd now owns 17,726 shares of the medical instruments supplier’s stock worth $4,484,000 after acquiring an additional 428 shares in the last quarter. Voya Investment Management LLC grew its holdings in Becton Dickinson and by 29.6% in the third quarter. Voya Investment Management LLC now owns 478,546 shares of the medical instruments supplier’s stock valued at $121,053,000 after purchasing an additional 109,227 shares during the period. Finally, Colony Group LLC lifted its holdings in Becton Dickinson and by 0.7% during the third quarter. Colony Group LLC now owns 16,052 shares of the medical instruments supplier’s stock valued at $4,060,000 after purchasing an additional 110 shares in the last quarter. 84.65% of the stock is owned by hedge funds and other institutional investors.
Becton Dickinson and stock opened at $255.73 on Wednesday. The firm has a market capitalization of $69.91 billion, a P/E ratio of 22.13, a PEG ratio of 1.82 and a beta of 1.07. The stock has a fifty day moving average price of $251.93 and a 200 day moving average price of $249.17. Becton Dickinson and Co has a 52 week low of $208.62 and a 52 week high of $264.74. The company has a current ratio of 1.18, a quick ratio of 0.72 and a debt-to-equity ratio of 0.86.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Tuesday, December 10th will be given a dividend of $0.79 per share. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.77. The ex-dividend date is Monday, December 9th. This represents a $3.16 annualized dividend and a yield of 1.24%. Becton Dickinson and’s dividend payout ratio is 26.37%.
In related news, EVP James C. Lim sold 9,299 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $263.53, for a total value of $2,450,565.47. Following the completion of the sale, the executive vice president now directly owns 33,041 shares in the company, valued at approximately $8,707,294.73. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Charles R. Bodner sold 1,514 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $260.08, for a total value of $393,761.12. Following the completion of the transaction, the senior vice president now directly owns 5,180 shares in the company, valued at $1,347,214.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,345 shares of company stock worth $5,847,029. 0.12% of the stock is currently owned by insiders.
Several equities analysts have weighed in on BDX shares. Piper Jaffray Companies decreased their target price on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Wells Fargo & Co upped their target price on shares of Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a research note on Friday, September 6th. Finally, KeyCorp reduced their price objective on shares of Becton Dickinson and from $262.00 to $256.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. Five equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Becton Dickinson and has a consensus rating of “Buy” and a consensus target price of $266.00.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Article: Initial Coin Offerings entail a high degree of risk
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.